CT-388
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Roche · Phase 2 · Completed · Enrollment 447
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Arm 1: Placebo | Obesity + T2D | n/r | 48 | n/r | n/r |
| Arm 2: Enicepatide Dose Level 1 (Low) | Obesity + T2D | n/r | 48 | n/r | n/r |
| Arm 3: Enicepatide Dose Level 2 | Obesity + T2D | n/r | 48 | n/r | n/r |
| Arm 4: Enicepatide Dose Level 3 | Obesity + T2D | n/r | 48 | n/r | n/r |
| Arm 5: Enicepatide Dose Level 4 (High) | Obesity + T2D | n/r | 48 | n/r | n/r |